Affiliation:
1. Eli Lilly and Company; Indianapolis Indiana USA
Subject
Pharmacology (medical),Modeling and Simulation
Reference27 articles.
1. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050;Fridman;J. Immunol.,2010
2. JAKs and STATs in immunity, immunodeficiency, and cancer;O'Shea;N. Engl. J. Med.,2013
3. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo;Kremer;Arthritis Rheum.,2009
4. A randomized placebo-controlled study of INCB018424, a selective Janus kinase 1 & 2 (JAK1 & 2) inhibitor in rheumatoid arthritis (RA);Williams;Arthritis Rheum.,2008
5. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate;Keystone;Ann. Rheum. Dis.,2015
Cited by
23 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献